Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/52—Adding ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to a method for producing a plant extract from Desmodium, and more specifically Desmodium adscendens.
• ALT alanine aminotransferase
• AST aspartate aminotransferase
• ALT is only present in the cytoplasm, while AST also occurs in the mitochondria.
• the transaminases rise rapidly, since they are released even during cell wall injury.
• AST rises later than ALT and indicates that more serious necrosis is occurring.
• Membrane enzymes such as gamma-glutamyl transferase (yGT) and alkaline phosphatase (AP) are present in the cell membranes of almost all of the body's cells.
• liver diseases were very difficult to treat on the one hand, and even almost impossible to avoid, on the other hand. So this is also the problem raised here: how to prevent these liver diseases.
• Desmodium preparation including pinitol as "whole" or totum, with regard to the above documents, which yet mention the presence of pinitol in other Desmodium species, which does not mean although that the occurrence of pinitol in Desmodium adscendens can be expected, on the contrary. That seems all too short-sighted. Indeed, the fact that other Desmodium species, which are different from D. adscendens, appear to contain pinitol, has no predictive value on the presence or absence of this product pinitol in D. adscendens. It is generally known that the medicinal properties of a particular plant species are very often exclusively limited to said only one kind, and these are not present in other species of the same genus and/or family.
• D.A. from Desmodium family is mainly intended against certain diseases as further specified, or also like Papaver somniferum versus morphine.
• xylitol has the same number of hydroxyl groups as D-pinitol, which in this case is a decisive factor, since the derivatisation reaction takes place on the hydroxyl groups.
• below-ground plant parts of D.A. which are actually more season-independent, can also be used for preparing said plant extract.
• plant parts of said Desmodium adscendens can be used, in particular leaves, stems, branches and/or other above-ground parts, but also below-ground parts thereof, and if desired, also blossoms and fruits, or even the seeds thereof.
• said fraction of Desmodium adscendens is first ground, in particular into powdered form.
• This powder can optionally be converted directly to a pharmaceutical form.
• an aqueous decoction of said leaves and/or branches of Desmodium adscendens is then prepared as a decoction by boiling a certain quantity of dried, optionally powdered, leaves in a certain quantity of water, in particular distilled water, for a certain amount of time, especially 5 x 200 g, 3 L, and 1 hour, respectively.
• said aqueous decoction of the Desmodium adscendens plant parts used, such as leaves or branches, is then cooled; still more particularly wherein the portions obtained are then combined and filtered, after which the filtrate obtained is concentrated, especially under vacuum, and then freeze-dried or spray-dried.
• a standardised extract is derived from the plant Desmodium adscendens, quantified for D-pinitol in terms of its effect on hepatitis, in particular preventive, with the separation of D-pinitol from Desmodium adscendens, wherein D-pinitol forms an active constituent, in particular regarding liver injury of chemical, physical, infectious or immunologic origin.
• D-pinitol has immunopharmacologic properties and that D-pinitol decreases the expression of MHC-I, MHC-II and co-stimulators such as CD80 and CD86, both in vitro and in vivo, by suppressing MAPKs activation and translocation of NF-kB, and reduces the production of large quantities of IL-12 and pro-inflammatory cytokines in LPS-induced dendritic bone marrow cells. This results in the inhibition of maturation of these cells.
• Fig. 11 is a graphical representation of this, in which 1 represents 50 ml-30 min, 2 represents 50 ml-1 h, 3 represents 100 ml-30 min and 4 represents 100 ml-1 h, respectively.
• Table 22 shows the standard deviations, relative standard deviations expressed in per cent, RSD HO rwitz and maximum relative standard deviations.
• Table 23 below shows the recovery values with mean, standard deviation, relative standard deviation and 95% confidence interval.
• Fig. 22 shows a partial chromatogram of the analysis with internal standard. No interferences were present at the location of xylitol in the chromatogram.
• Figure 38 shows serum ALT levels after 6 weeks of ethanol administration, *** p ⁇ 0,001 vs HEP CON; ⁇ p ⁇ 0,05 vs HEP DES 1 , DES2, PIN, SIL (Mixed model analysis).
• test solutions for preparing the samples (test solutions), in each case about 100 mg powder (lyophilisate) is weighed into a 25,0 ml volumetric flask and 20 ml 50% methanol is added. The solutions are then sonicated for 15 minutes in the ultrasonic bath. After the samples are cooled, they are diluted to 25,0 ml with 50% methanol. Both the test solution(s) and the reference solution(s) are filtered through a nylon syringe filter.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Botany (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Biotechnology (AREA)
• Alternative & Traditional Medicine (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Addiction (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Neurosurgery (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Child & Adolescent Psychology (AREA)
• Toxicology (AREA)
• Psychiatry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Emergency Medicine (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=48463649

Family Applications (1)

Country Status (8)

Cited By (6)

Families Citing this family (6)

Citations (2)

Family Cites Families (2)

• 2012
  • 2012-03-20 BE BE201200195A patent/BE1020835A5/nl not_active IP Right Cessation
• 2013
  • 2013-03-20 JP JP2015500720A patent/JP2015515457A/ja active Pending
  • 2013-03-20 IN IN8769DEN2014 patent/IN2014DN08769A/en unknown
  • 2013-03-20 WO PCT/BE2013/000014 patent/WO2013166563A1/en not_active Ceased
  • 2013-03-20 CA CA2868128A patent/CA2868128A1/en not_active Abandoned
  • 2013-03-20 CN CN201380022605.4A patent/CN104661668A/zh active Pending
  • 2013-03-20 US US14/386,237 patent/US20150050368A1/en not_active Abandoned
  • 2013-03-20 EP EP13723395.3A patent/EP2849769B1/en active Active

Patent Citations (2)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events